JP2025163108A5 - - Google Patents
Info
- Publication number
- JP2025163108A5 JP2025163108A5 JP2025127141A JP2025127141A JP2025163108A5 JP 2025163108 A5 JP2025163108 A5 JP 2025163108A5 JP 2025127141 A JP2025127141 A JP 2025127141A JP 2025127141 A JP2025127141 A JP 2025127141A JP 2025163108 A5 JP2025163108 A5 JP 2025163108A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- stable liquid
- aqueous pharmaceutical
- liquid aqueous
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897930P | 2019-09-09 | 2019-09-09 | |
| US62/897,930 | 2019-09-09 | ||
| PCT/IB2020/058347 WO2021048743A1 (en) | 2019-09-09 | 2020-09-09 | Anti-il-23p19 antibody formulations |
| JP2022515471A JP2022547162A (ja) | 2019-09-09 | 2020-09-09 | 抗ＩＬ－２３ｐ１９抗体製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515471A Division JP2022547162A (ja) | 2019-09-09 | 2020-09-09 | 抗ＩＬ－２３ｐ１９抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025163108A JP2025163108A (ja) | 2025-10-28 |
| JP2025163108A5 true JP2025163108A5 (enExample) | 2025-12-15 |
Family
ID=72615913
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515471A Pending JP2022547162A (ja) | 2019-09-09 | 2020-09-09 | 抗ＩＬ－２３ｐ１９抗体製剤 |
| JP2025127141A Pending JP2025163108A (ja) | 2019-09-09 | 2025-07-30 | 抗ＩＬ－２３ｐ１９抗体製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515471A Pending JP2022547162A (ja) | 2019-09-09 | 2020-09-09 | 抗ＩＬ－２３ｐ１９抗体製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210070852A1 (enExample) |
| EP (1) | EP4028419A1 (enExample) |
| JP (2) | JP2022547162A (enExample) |
| KR (1) | KR20220062359A (enExample) |
| CN (1) | CN114340674A (enExample) |
| AU (1) | AU2020345071A1 (enExample) |
| BR (1) | BR112022003169A2 (enExample) |
| CA (1) | CA3147328A1 (enExample) |
| CL (1) | CL2024002086A1 (enExample) |
| IL (1) | IL291131A (enExample) |
| MX (1) | MX2022002850A (enExample) |
| PH (1) | PH12022550558A1 (enExample) |
| TW (2) | TW202535466A (enExample) |
| WO (1) | WO2021048743A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201705728RA (en) | 2015-02-04 | 2017-08-30 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| CN115135671A (zh) | 2019-12-20 | 2022-09-30 | 新石生物制药有限公司 | 抗白介素-23 p19的抗体及其使用方法 |
| WO2023019556A1 (zh) * | 2021-08-20 | 2023-02-23 | 齐鲁制药有限公司 | 一种高浓度抗her2的抗体制剂及其用途 |
| JP2025525317A (ja) * | 2022-06-15 | 2025-08-05 | アッヴィ・インコーポレイテッド | リサンキズマブ組成物 |
| IL319239A (en) | 2022-10-21 | 2025-04-01 | Chong Kun Dang Pharmaceutical Corp | Stable antibody preparation |
| WO2025071362A1 (ko) * | 2023-09-27 | 2025-04-03 | 삼성바이오에피스 주식회사 | 항-il-23 항체의 안정한 액상 제형 |
| WO2025137347A1 (en) * | 2023-12-20 | 2025-06-26 | Abbvie Inc. | High concentration risankizumab formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69620877T2 (de) * | 1995-02-06 | 2002-12-12 | Genetics Institute, Inc. | Arzneimittelformulierungen für il-12 |
| ATE556591T1 (de) * | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| PT1896073E (pt) * | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
| EP2331078B1 (en) * | 2008-08-27 | 2012-09-19 | Merck Sharp & Dohme Corp. | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| US9265834B2 (en) * | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| PE20141162A1 (es) * | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| KR102124758B1 (ko) * | 2012-05-03 | 2020-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-ｉｌ-23ｐ19 항체 |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| SG11201705728RA (en) * | 2015-02-04 | 2017-08-30 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| GB201612317D0 (en) * | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| WO2018071504A2 (en) * | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
| EP3810268A1 (en) * | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
-
2020
- 2020-09-08 TW TW113142787A patent/TW202535466A/zh unknown
- 2020-09-08 US US17/014,399 patent/US20210070852A1/en active Pending
- 2020-09-08 TW TW109130792A patent/TW202123965A/zh unknown
- 2020-09-09 BR BR112022003169A patent/BR112022003169A2/pt unknown
- 2020-09-09 AU AU2020345071A patent/AU2020345071A1/en active Pending
- 2020-09-09 KR KR1020227011838A patent/KR20220062359A/ko active Pending
- 2020-09-09 JP JP2022515471A patent/JP2022547162A/ja active Pending
- 2020-09-09 WO PCT/IB2020/058347 patent/WO2021048743A1/en not_active Ceased
- 2020-09-09 PH PH1/2022/550558A patent/PH12022550558A1/en unknown
- 2020-09-09 MX MX2022002850A patent/MX2022002850A/es unknown
- 2020-09-09 CA CA3147328A patent/CA3147328A1/en active Pending
- 2020-09-09 CN CN202080062754.3A patent/CN114340674A/zh active Pending
- 2020-09-09 EP EP20776232.9A patent/EP4028419A1/en active Pending
-
2022
- 2022-03-06 IL IL291131A patent/IL291131A/en unknown
-
2024
- 2024-07-10 CL CL2024002086A patent/CL2024002086A1/es unknown
-
2025
- 2025-07-30 JP JP2025127141A patent/JP2025163108A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025163108A5 (enExample) | ||
| JP2021155453A5 (enExample) | ||
| JP2024001364A5 (enExample) | ||
| RU2011140498A (ru) | Препарат антител | |
| JP2022166006A5 (enExample) | ||
| MX2014013998A (es) | Composiciones antimucosidad a base de xilitol y metodos y composiciones. | |
| RU2010119165A (ru) | Кортикостероидные композиции | |
| JP2005508981A5 (enExample) | ||
| JP2012505172A (ja) | パラセタモールを有する液体医薬製剤 | |
| HRP20250278T1 (hr) | Puferovane formulacije eksendina (9-39) | |
| JP2019536761A5 (enExample) | ||
| CN109044981A (zh) | 一种普瑞巴林胃漂浮型缓释片及其制备方法 | |
| JP5538568B2 (ja) | アセトアミノフェンの安定化剤 | |
| Leonards et al. | Aspirin‐induced occult gastrointestinal blood loss: Local versus systemic effects | |
| ES2303238T3 (es) | Preparacion granulada de liberacion lenta que contiene una droga con estructura de amina con base en particulas con una capa de recubrimiento y el correspondiente metodo de produccion. | |
| JP2022062153A5 (enExample) | ||
| Neha et al. | Formulation and development of vaginal films of poorly water soluble drug, metronidazole, using mixed solvency concept and their evaluations | |
| WO2016163403A1 (ja) | 経口フィルム製剤 | |
| CN102630162B (zh) | 4-甲基吡唑制剂 | |
| RU2008151945A (ru) | Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина | |
| KR101744538B1 (ko) | 콜린 알포세레이트를 함유하는 수성 액상 제제 | |
| JP2023116498A5 (enExample) | ||
| CN115998836A (zh) | 一种含有奈玛特韦和利托那韦的液体制剂及其制备方法与应用 | |
| Kwei et al. | Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs | |
| WO2003047550A1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno |